MedTrace Logo

Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis

NCT00295854 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 296

Last updated 2012-01-19

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and efficacy of 8 weeks of treatment with MN-001 at 500 mg bid, 500 mg once daily vs. placebo in patients with Interstitial Cystitis.

Conditions

  • Interstitial Cystitis

Interventions

DRUG

MN-001 BID

Eligible patients received 500 mg MN-001 bid

DRUG

MN-001

Eligible patients received 500 mg MN-001 once daily (qd)

DRUG

Placebo

Eligible patients received placebo

Sponsors & Collaborators

  • MediciNova

    lead INDUSTRY

Principal Investigators

  • Richard E Gammans, MD · MediciNova, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00295854 on ClinicalTrials.gov